Opzioni
Cardiac and Vascular Remodeling After 6 Months of Therapy With Sacubitril/Valsartan: Mechanistic Insights From Advanced Echocardiographic Analysis
2022
Periodico
FRONTIERS IN CARDIOVASCULAR MEDICINE
Abstract
Background: Effects of Sacubitril/Valsartan (S/V) on left ventricular (LV) mechanics and
ventricular-arterial coupling in patients with heart failure with reduced ejection fraction
(HFrEF) are not completely understood. The aim of this study was to evaluate both
cardiac and vascular remodeling in a group of HFrEF patients undergoing S/V therapy.
Methods: Fifty HFrEF patients eligible to start a therapy with S/V were enrolled.
Echocardiographic evaluation was performed at baseline and after 6 months of followup
(FU). Beside standard evaluation, including global longitudinal strain (GLS), estimated
hemodynamic forces (HDFs) and non-invasive pressure-volume curves (PV loop) were
assessed using dedicated softwares. HDFs were evaluated over the entire cardiac cycle,
in systole and diastole, both in apex to base (A-B) and latero-septal (L-S) directions. The
distribution of LV HDFs was evaluated by L-S over A-B HDFs ratio (L-S/A-B HDFs ratio).
Parameters derived from estimated PV loop curves were left ventricular end-systolic
elastance (Ees), arterial elastance (Ea), and ventricular-arterial coupling (VAC).
Results: At 6 months of FU indexed left ventricular end-diastolic and end-systolic
volumes decreased (EDVi: 101 ± 28mL vs. 86 ± 30mL, p < 0.001; ESVi: 72 ± 23mL
vs. 55 ± 24mL, p < 0.001), ejection fraction and GLS significantly improved (EF: 29 ±
6% vs. 37 ± 7%, p < 0.001; GLS: −9 ± 3% vs. −13 ± 4%, p < 0.001). A reduction of
Ea (2.11 ± 0.91 mmHg/mL vs. 1.72 ± 0.44 mmHg/mL, p = 0.008) and an improvement
of Ees (1.01 ± 0.37 mmHg/mL vs. 1.35 ± 0.6 mmHg/mL, p < 0.001) and VAC (2.3 ±
1.1 vs. 1.5 ± 0.7, p < 0.001) were observed. Re-alignment of HDFs occurred, with a
reduction of diastolic L-S/A-B HDFs ratio [23 (20–35)% vs. 20 (11–28) %, p < 0.001].
Conclusion: S/V therapy leads to a complex phenomenon of reverse remodeling
involving increased myocardial contractility, HDFs distribution improvement, and
afterload reduction.
Diritti
open access
license:creative commons
license uri:http://creativecommons.org/licenses/by-sa/4.0/